JP Morgan Chase
HRTX icon

JP Morgan Chase’s Heron Therapeutics HRTX Stock Holding History

JP Morgan Chase’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48.6K Buy
65,106
+2,710
+4% +$3.14K ﹤0.01% 6211
2025
Q4 		$81.1K Sell
62,396
-1,230,048
-95% -$1.52M ﹤0.01% 5995
2025
Q3 		$1.63M Buy
1,292,444
+339,364
+36% +$538K ﹤0.01% 4233
2025
Q2 		$1.97M Buy
953,080
+256,637
+37% +$524K ﹤0.01% 3933
2025
Q1 		$1.53M Buy
696,443
+133,679
+24% +$259K ﹤0.01% 4056
2024
Q4 		$861K Buy
562,764
+356,053
+172% +$577K ﹤0.01% 4736
2024
Q3 		$411K Buy
206,711
+154,487
+296% +$369K ﹤0.01% 5030
2024
Q2 		$183K Buy
52,224
+9,740
+23% +$29.9K ﹤0.01% 5202
2024
Q1 		$118K Sell
42,484
-33,137
-44% -$83.3K ﹤0.01% 5604
2023
Q4 		$129K Sell
75,621
-6,734,321
-99% -$7.42M ﹤0.01% 5617
2023
Q3 		$7.01M Sell
6,809,942
-45,669
-0.7% -$65K ﹤0.01% 2580
2023
Q2 		$7.95M Sell
6,855,611
-231,180
-3% -$412K ﹤0.01% 2488
2023
Q1 		$10.7M Buy
7,086,791
+332,792
+5% +$833K ﹤0.01% 2219
2022
Q4 		$16.9M Buy
6,753,999
+59,315
+0.9% +$191K ﹤0.01% 1798
2022
Q3 		$28.3M Sell
6,694,684
-190,993
-3% -$747K ﹤0.01% 1353
2022
Q2 		$19.2M Buy
6,885,677
+759,541
+12% +$3.05M ﹤0.01% 1648
2022
Q1 		$35M Sell
6,126,136
-128,630
-2% -$941K ﹤0.01% 1371
2021
Q4 		$57.1M Buy
6,254,766
+952,969
+18% +$9.73M 0.01% 1143
2021
Q3 		$56.7M Buy
5,301,797
+791,695
+18% +$9.64M 0.01% 1117
2021
Q2 		$70M Buy
4,510,102
+1,236,981
+38% +$19.7M 0.01% 1066
2021
Q1 		$53.1M Buy
3,273,121
+172,339
+6% +$3.07M 0.01% 1135
2020
Q4 		$65.6M Buy
3,100,782
+122,187
+4% +$2.12M 0.01% 960
2020
Q3 		$44.2M Buy
2,978,595
+141,188
+5% +$2.2M 0.01% 1037
2020
Q2 		$41.7M Buy
2,837,407
+259,665
+10% +$4.27M 0.01% 975
2020
Q1 		$30.3M Buy
2,577,742
+555,540
+27% +$10.4M 0.01% 1030
2019
Q4 		$47.5M Buy
2,022,202
+486,493
+32% +$10.8M 0.01% 993
2019
Q3 		$28.4M Buy
1,535,709
+110,192
+8% +$2.03M 0.01% 1328
2019
Q2 		$26.3M Buy
1,425,517
+535,821
+60% +$10.7M 0.01% 1365
2019
Q1 		$21.7M Buy
889,696
+677,354
+319% +$17.7M ﹤0.01% 1485
2018
Q4 		$5.51M Buy
212,342
+5,540
+3% +$152K ﹤0.01% 2498
2018
Q3 		$6.54M Sell
206,802
-10,262
-5% -$382K ﹤0.01% 2524
2018
Q2 		$8.43M Sell
217,064
-25,747
-11% -$820K ﹤0.01% 2281
2018
Q1 		$6.7M Sell
242,811
-42,397
-15% -$962K ﹤0.01% 2332
2017
Q4 		$5.16M Buy
285,208
+283,000
+12,817% +$4.61M ﹤0.01% 2653
2017
Q3 		$35K Buy
2,208
+164
+8% +$2.57K ﹤0.01% 4542
2017
Q2 		$28K Sell
2,044
-67,308
-97% -$975K ﹤0.01% 4469
2017
Q1 		$1.04M Buy
69,352
+1,897
+3% +$26.3K ﹤0.01% 3390
2016
Q4 		$884K Buy
67,455
+2,363
+4% +$37.1K ﹤0.01% 3500
2016
Q3 		$1.12M Sell
65,092
-271,796
-81% -$5.04M ﹤0.01% 3078
2016
Q2 		$6.08M Sell
336,888
-11,797
-3% -$230K ﹤0.01% 2158
2016
Q1 		$6.62M Buy
348,685
+19,737
+6% +$389K ﹤0.01% 2039
2015
Q4 		$8.78M Buy
328,948
+156,259
+90% +$4.18M ﹤0.01% 1899
2015
Q3 		$4.21M Buy
+172,689
New +$5.76M ﹤0.01% 2332
2015
Q1 		– Sell
-17,469
Closed -$176K – 4155
2014
Q4 		$176K Buy
+17,469
New +$143K ﹤0.01% 4046

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

JP Morgan Chase's HRTX Position: Q1 2026 in Review

JP Morgan Chase increased its Heron Therapeutics (HRTX) stake by 4.3% in Q1 2026, buying an estimated $3.14K and bringing the position to 65,106 shares worth $48.6K. The position accounts for ﹤0.01% of the portfolio, ranked #6211.

JP Morgan Chase first reported a position in HRTX in Q4 2014 and has held it in 44 quarters since. The position peaked at $70M in Q2 2021. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • JP Morgan Chase held 65,106 shares of Heron Therapeutics worth $48.6K as of Q1 2026.
  • JP Morgan Chase bought 2,710 Heron Therapeutics shares in Q1 2026, an estimated $3.14K.
  • Heron Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6211 holding.
  • JP Morgan Chase first reported a position in Heron Therapeutics in Q4 2014 and has held it in 44 quarters since.
  • JP Morgan Chase's Heron Therapeutics position peaked at $70M in Q2 2021.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.